
New Colorimetric Sensor Shortens Antibiotic Susceptibility Testing to 5 Hours
The global antimicrobial resistance (AMR) crisis requires urgent innovation in diagnostic technology. Consequently, researchers have developed a Rapid Phenotypic AST platform that uses a dual-enzyme cascade colorimetric sensor (DECCS) to provide results within just five hours. This breakthrough significantly improves the speed of evidence-based antimicrobial prescribing.
Traditionally, phenotypic antimicrobial susceptibility testing (AST) takes 18 to 24 hours. This delay often forces clinicians to rely on empirical antibiotic treatments. Unfortunately, empirical therapy can compromise patient outcomes and accelerate the emergence of resistant strains. The DECCS system addresses this by transducing bacterial glucose metabolic activity into a quantitative colorimetric signal.
Mechanism of the Rapid Phenotypic AST Sensor
The sensor utilizes a glucose oxidase (GOD) and horseradish peroxidase (HRP) dual-enzyme cascade. When bacteria remain metabolically active, the system produces a visible color change. Clinicians can read these results with the naked eye or validate them using smartphone-based RGB analysis. Furthermore, microplate reader absorbance measurements provide an extra layer of analytical precision.
Researchers validated the performance of this platform using 155 clinical isolates and five reference strains. The pathogens tested included Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae. Remarkably, the sensor achieved 96% essential agreement and 98% categorical agreement with the gold-standard broth microdilution method.
Clinical Significance for Resource-Limited Settings
This new method is particularly suitable for resource-limited clinical settings. It features a simplified workflow, low operational costs, and multiple readout capabilities. Therefore, it provides a practical alternative to strengthen antimicrobial stewardship efforts globally. By providing same-day results, the sensor helps clinicians optimize bacterial infection treatment and reduce unnecessary antibiotic use.
Frequently Asked Questions
How does the DECCS method compare to traditional broth microdilution?
The DECCS method demonstrates high concordance with the gold standard, achieving 98% categorical agreement. However, it delivers these results in roughly 5 hours instead of the traditional 18-24 hour window.
Can this sensor detect resistance in both Gram-positive and Gram-negative bacteria?
Yes, the performance validation covered major pathogens from both groups, including Pseudomonas aeruginosa and Acinetobacter baumannii. It accurately identifies minimum inhibitory concentration (MIC) values for a variety of clinical isolates.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zhang X et al. Bacterial Metabolism-Driven Dual-Enzyme Cascade Colorimetric Sensor for Antimicrobial Susceptibility Testing with Readily Interpretable Signals. Anal Chem. 2026 Mar 23. doi: 10.1021/acs.analchem.5c07762. PMID: 41867145.
Vasala A et al. Next-generation rapid phenotypic antimicrobial susceptibility testing. Lancet Infect Dis. 2024 Nov 09.
Tsalik EL et al. Emerging Technologies for Rapid Phenotypic Antimicrobial Susceptibility Testing of Clinical Isolates of Bacteria. Clin Microbiol Rev. 2022 Dec 01.

More from MedShots Daily

A new dual-enzyme sensor enables rapid phenotypic antimicrobial susceptibility testing in 5 hours, matching gold-standard accuracy for major pathogens....
last month

A global survey reveals that despite high treatment compliance, many haemophilia patients still suffer from joint issues and frequent bleeding episodes....
Today

A new study reveals that disclosing Breast Cancer Polygenic Risk Scores significantly reduces decisional conflict for women with BRCA1/2 variants....
Today

Procizumab is a humanized antibody that neutralizes circulating DPP3, a biological driver of shock, by preventing angiotensin II degradation....
Today

Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....
Today

Research highlights sex-specific roles of oxytocin neurons in the hypothalamus and signaling in the nucleus accumbens regarding juvenile social play behavio...
Today